Published on September 9, 2009 at 2:36 AM
NanoBio Corp. announced today that data from a large ferret study indicates that its intranasal, nanoemulsion-based adjuvant elicits robust immunity and cross protection against influenza using 1/15th of the standard antigen dose, without evidence of toxicity or tolerability concerns. The company also announced that data from a large GLP toxicity study in rabbits demonstrated similarly robust immune responses without signs of toxicity or inflammation.
Data from both studies will be presented on Sunday, September 13th at 11:15 am at the 49th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) at the Moscone Center, San Francisco, CA. The poster references are as follows:
Poster # G1-877: Intranasal W805EC Adjuvanted Fluzone Provides Robust Immunity and Cross-Protection in Ferrets
Poster # G1-878: A GLP Toxicity and Immunogenicity Study of NB-1008, an Intranasal W805EC-Adjuvanted-Fluzone Vaccine
NanoBio will sponsor corporate booth # 1711 at ICAAC, where information on the company’s development programs for its vaccine, dermatological and anti-infective programs will be available.
http://www.nanobio.com/
385b00e5-6125-4e94-ab57-5220a1f5136e|0|.0
Posted in: Medical Science News
Tags: Acne, Anthrax, Antigen, Chemotherapy, Cold Sores, Cystic Fibrosis, Fibrosis, Hepatitis B, Herpes, Herpes Labialis, Influenza, Pandemic, Smallpox, Vaccine